Adjuvant Dose Dense Chemotherapy in Patients With Obesity: Short-Term Toxicities and Breast Cancer Outcome.
- Published in:
- Clinical Breast Cancer, 2023, v. 23, n. 5, p. 491, doi. 10.1016/j.clbc.2023.03.008
- By:
- Publication type:
- Article
Works matching IS 15268209 AND DT 2023 AND VI 23 AND IP 5
Results: 9
1
2
Disparate Utilization of Breast Conservation Therapy in the Surgical Management of Early-Stage Breast Cancer.
- Published in:
- Clinical Breast Cancer, 2023, v. 23, n. 5, p. 561, doi. 10.1016/j.clbc.2023.04.008
- By:
- Publication type:
- Article
3
m6A Modification Mediates Exosomal LINC00657 to Trigger Breast Cancer Progression Via Inducing Macrophage M2 Polarization.
- Published in:
- Clinical Breast Cancer, 2023, v. 23, n. 5, p. 546, doi. 10.1016/j.clbc.2023.04.007
- By:
- Publication type:
- Article
4
Development and Validation of a Nomogram for Predicting Axillary Lymph Node Metastasis in Breast Cancer.
- Published in:
- Clinical Breast Cancer, 2023, v. 23, n. 5, p. 538, doi. 10.1016/j.clbc.2023.04.002
- By:
- Publication type:
- Article
5
Genetic Ancestry of 1127 Brazilian Breast Cancer Patients and Its Correlation With Molecular Subtype and Geographic Region.
- Published in:
- Clinical Breast Cancer, 2023, v. 23, n. 5, p. 527, doi. 10.1016/j.clbc.2023.04.001
- By:
- Publication type:
- Article
6
Machine Learning Approach for the Determination of the Best Cut-Off Points for Ki67 Proliferation Index in Adjuvant and Neo-Adjuvant Therapy Breast Cancer Patients.
- Published in:
- Clinical Breast Cancer, 2023, v. 23, n. 5, p. 519, doi. 10.1016/j.clbc.2023.03.015
- By:
- Publication type:
- Article
7
Cost-effectiveness and Value-based Pricing of Trastuzurnab Deruxtecan in Metastatic Breast Cancer With Low HER2 Expression.
- Published in:
- Clinical Breast Cancer, 2023, v. 23, n. 5, p. 508, doi. 10.1016/j.clbc.2023.03.013
- By:
- Publication type:
- Article
8
Performance of Supplemental Imaging Modalities for Breast Cancer in Women With Dense Breasts: Findings From an Umbrella Review and Primary Studies Analysis.
- Published in:
- Clinical Breast Cancer, 2023, v. 23, n. 5, p. 478, doi. 10.1016/j.clbc.2023.04.003
- By:
- Publication type:
- Article
9
Germline BRCA-Mutated HER2-Negative Advanced Breast Cancer: Overcoming Challenges in Genetic Testing and Clinical Considerations When Using Talazoparib.
- Published in:
- Clinical Breast Cancer, 2023, v. 23, n. 5, p. 469, doi. 10.1016/j.clbc.2023.04.006
- By:
- Publication type:
- Article